Skip to main content

Merck & Co., Inc. Q3 FY2026 results

  • MRK · NYSE
  • Pharmaceuticals
  • S&P 500
$147.76+0.55%Close 13 Nov 2026 · Market value $361.6B

Merck & Co., Inc. reported revenue of $18.1 billion, up 4.7% from a year earlier, net income of $5.07 billion and diluted earnings per share of $2.04 against $2.32 for the third quarter of fiscal 2026 (the three months to 30 Sep 2026).

From its quarterly report, the results first announced on 29 Oct 2026. Compiled and checked by AapWire.

Q3 FY2026 against Q3 FY2025

Three months to 30 Sep 2026, against the three months to 30 Sep 2025. Amounts in USD.

Merck & Co., Inc. Q3 FY2026 results against the year-ago quarter
MeasureQ3 FY2026Q3 FY2025Change
Revenue$18.09B$17.28B+4.7%
Gross profit$13.19B$13.42B−1.7%
Gross margin72.9%77.7%−4.7 pts
Operating income$6.11B$7.07B−13.7%
Operating margin33.8%40.9%−7.2 pts
Net income$5.07B$5.79B−12.4%
Diluted EPS$2.04$2.32−12.1%
Operating cash flow$6.56B$7.82B−16.2%
Capital expenditure$1.04B$987.0M+5.4%
Free cash flow$5.52B$6.83B−19.3%

Operating KPIs for the quarter

Merck & Co., Inc. operating KPIs, Q3 FY2026
KPIQ3 FY2026Change on a year
Keytruda revenue$7.8Bdown 4.6%
Gardasil/Gardasil 9 revenue$2.0Bup 14.1%
Livestock revenue$1.0Bup 2.4%
Keytruda Qlex revenue$830.0M—
ProQuad/M-M-R II/Varivax revenue$730.0Mup 6.7%
Winrevair revenue$694.0Mup 92.8%
Companion Animal revenue$628.0Mup 6.1%
Lynparza alliance revenue$352.0Mdown 7.1%
Prevymis revenue$347.0Mup 30.5%
Welireg revenue$307.0Mup 56.6%
Lenvima alliance revenue$287.0Mup 11.2%
Capvaxive revenue$263.0Mup 7.8%
RotaTeq revenue$196.0Mdown 3.9%
Vaxneuvance revenue$195.0Mdown 13.7%
Janumet revenue$194.0Mdown 20.2%
Januvia revenue$186.0Mdown 51.3%
Ohtuvayre revenue$184.0M—
Reblozyl alliance revenue$177.0Mup 30.1%
Bridion revenue$144.0Mdown 67.2%
Adempas/Verquvo alliance revenue$118.0Mup 5.4%

Earlier quarters

Merck & Co., Inc. results, last eight filed quarters
QuarterPeriod endRevenueChange on a yearDiluted EPS
Q3 FY202630 Sep 2026$18.09B+4.7%$2.04
Q2 FY202630 Jun 2026$16.61B+5.1%−$0.54
Q1 FY202631 Mar 2026$16.29B+4.9%−$1.72
Q4 FY202531 Dec 2025$16.40B+5.0%$1.19
Q3 FY202530 Sep 2025$17.28B+3.7%$2.32
Q2 FY202530 Jun 2025$15.81B−1.9%$1.76
Q1 FY202531 Mar 2025$15.53B−1.6%$2.01
Q4 FY202431 Dec 2024$15.62B+6.8%$1.48

More on Merck & Co., Inc.: financial statements · revenue · earnings per share

MRK's results, as they are filed.

Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.